目的 探討卡介菌多糖核酸聯(lián)合異丙托溴銨治療支氣管哮喘的臨床療效。方法 選取2016年4月—2017年4月在南陽市中心醫(yī)院治療的支氣管哮喘患者74例，隨機(jī)分為對(duì)照組（37例）和治療組（37例）。對(duì)照組霧化吸入異丙托溴銨氣霧劑，2撳/次，2次/d；治療組在對(duì)照組基礎(chǔ)上靜脈滴注卡介菌多糖核酸注射液，1 mL/次，3次/周。兩組患者均治療4周。觀察兩組患者臨床療效，比較治療前后兩組患者肺功能、血清學(xué)指標(biāo)、臨床癥狀評(píng)分和PAQLQ各維度評(píng)分。結(jié)果 治療后，對(duì)照組和治療組臨床總有效率分別為81.08%和97.30%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者1秒用力呼氣容積（FEV1）、用力肺活量（FVC）、最大呼氣流速（PEF）均顯著升高（P<0.05）；且治療組患者上述肺功能指標(biāo)水平明顯高于對(duì)照組（P<0.05）。治療后，兩組患者血清IL-4、基質(zhì)金屬蛋白酶-9（MMP-9）和基質(zhì)金屬蛋白酶天然抑制劑-1（TIMP-1）水平均顯著降低，IL-2和IFN-γ水平顯著升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組患者血清學(xué)指標(biāo)顯著優(yōu)于對(duì)照組（P<0.05）。治療后，兩組患者胸悶、喘息、咳嗽和哮鳴音等評(píng)分均明顯降低（P<0.05）；且治療組比對(duì)照組降低更顯著（P<0.05）。治療后，兩組PAQLQ各維度評(píng)分均明顯升高（P<0.05）；且治療組比對(duì)照組升高更顯著（P<0.05）。結(jié)論 卡介菌多糖核酸聯(lián)合異丙托溴銨治療支氣管哮喘可有效改善患者臨床癥狀，利于患者肺功能改善。

objective To investigate the clinical efficacy of BCG polysaccharide and nucleic acid combined with ipratropium bromide in treatment of bronchial asthma. Methods Patients (74 cases) with bronchial asthma in Nanyang City Central Hospital from April 2016 to April 2017 were randomly divided into control (37 cases) and treatment (37 cases) groups. Patients in the control group were atomization inhalation administered with Ipratropium Bromide Aerosol, 2 presses/time, twice daily. Patients in the treatment group were iv administered with BCG Polysaccharide and Nucleic Acid Injection on the basis of the control group, 1 mL/time, three times weekly. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the pulmonary function, serum markers, the clinical symptom scores and PAQLQ scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.08% and 97.30%, respectively, and there were differences between two groups (P < 0.05). After treatment, the FEV1, FVC and PEF in two groups were significantly increased (P < 0.05). And these pulmonary function indexes levels in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the IL-4, MMP-9 and TIMP-1 levels in two groups were significantly decreased, but the IL-2 and IFN-γ levels were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And these serum markers in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the chest tightness, wheezing, coughing and wheezing scores in two groups were significantly decreased (P < 0.05). And these clinical symptom scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the PAQLQ scores in two groups were significantly increased (P < 0.05). And these PAQLQ scores in the treatment group increased more significantly than those in the control group (P < 0.05). Conclusion BCG polysaccharide and nucleic acid combined with ipratropium bromide in treatment of bronchial asthma can effectively improve the clinical symptoms and lung function.